Nerlynx (neratinib tablets - Puma) — Cigna

Breast Cancer – Recurrent or Metastatic HER2-Negative Disease

Initial criteria

Patient age ≥ 18 years AND
Patient has HER2-negative breast cancer AND
The cancer has a HER2-activating mutation (e.g., L755S, D769H/Y, V777L, exon 20 insertion) AND
EITHER (Patient is a postmenopausal female or a male) OR (Patient is a pre/perimenopausal female receiving ovarian suppression/ablation with a GnRH agonist or has had surgical bilateral oophorectomy/ovarian irradiation) AND
EITHER (Patient has hormone receptor (HR)-positive disease AND has tried at least one CDK4/6 inhibitor therapy) OR (Patient has HR-negative disease)

1 year